National Institutes of Health

SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.

Neuronoff, a medical device company, is focused on the development of the Injectrode™, a novel injectable metal electrode, which is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets.

IVOS Medical is an innovative medical device company focused on advancing airway management technology.

Rhealth is a biotechnology company that focuses on delivering advanced health management solutions through an AI-driven platform tailored for hospitals. It aims to enhance the accessibility of analytical and diagnostic information for both physicians and patients. By integrating portable diagnostic and monitoring technologies, Rhealth seeks to transform the way health information is accessed and utilized, ultimately enabling healthcare providers to deliver more timely and effective care.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

BioCircuit Technologies develops noninvasive electrophysiology devices which monitor, control and repair peripheral nerves. ​ BioCircuit’s products provide clinicians with a practical ability to diagnose health conditions earlier, track the progression of symptoms over time, and select treatments more precisely for individual patients.

BMI OrganBank specializes in the development of advanced medical devices and perfusion technology aimed at enhancing the preservation of organs and tissues for transplantation. By collaborating with academic institutions, the company seeks to expand the potential of organ transplantation and improve patient outcomes. Its focus includes innovative solutions that could significantly transform kidney transplantation and other organ preservation methods, ultimately benefiting thousands of patients in need of transplants. The company’s efforts also extend to developing technologies for organ preservation, such as lung ventilators and ex vivo tissue perfusion, which enable healthcare providers to deliver better medical care.

Novel Microdevices, LLC is focused on developing handheld devices for molecular diagnostics, specifically through its product, NOVEL DX. This innovative device utilizes microfluidics technology to analyze raw biological samples directly at the point of care, providing results in just 30 minutes. By enabling healthcare professionals to achieve lab-quality results without the need for a traditional laboratory setting, the device addresses various sectors including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture. Founded in 2014 by Andrea Pais, Novel Microdevices is headquartered in Baltimore, Maryland.

CareTaker is the worlds most innovative patient monitor Using only a simple finger cuff to measure Continuous Beat-by-Beat Blood Pressure (“cNIBP”), Heart Rate, and other physiological parameters enabling safe, secure, and accurate remote patient monitoring via their secure Android App, HIPPA-compliant Cloud Portals, or interfaced with other patient monitoring systems. CareTaker sets a new standard in mobility, simplicity, and cost, enabling continuous realtime monitoring as patients traverse the full continuum of care, within the hospital, during transport, and after discharge.

Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical cancer screenings. We believe that it’s time for women’s health to be designed for women, their preferences, and their experiences. With this in mind, Teal Health is creating the first FDA-approved at-home cervical cancer screening making it simple for a woman to stay current on this life-saving screening from the comfort, convenience, and privacy of her home. Through timely screenings, Teal health plans to eradicate cervical cancer in the US. Teal is backed by passionate and committed investors who share this important vision, including Felicis Ventures, Emerson Collective, Metrodora, and Serena Ventures.

Lasarrus develops devices for patients with chronic obstructive pulmonary disease. The company was founded in 2013 and is headquartered in Baltimore, Maryland.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Penderia Technologies is a new medical device company that specializes in creative ways to treat orthopedic ailments.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Annoviant is a healthcare company focused on the development of innovative medical devices, specifically tissue-based valve and conduit replacement products. These devices are designed to replace or repair structures that are congenitally absent or underdeveloped. Annoviant's offerings are characterized by their regenerative capabilities and resistance to thrombosis, calcification, and infection. By maintaining essential mechanical properties, these devices aim to enhance clinical outcomes for substitute conduit arteries in infants and children, ultimately reducing the need for repeated surgical interventions.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

Virtuoso Surgical focuses on developing robotic tools specifically for minimally invasive endoscopic surgery. The company's surgical system features needle-sized robotic arms that allow surgeons to navigate and operate in hard-to-reach areas of the body, addressing limitations posed by traditional endoscopes. By providing dexterous and accurate instruments, Virtuoso Surgical aims to enhance surgical precision and improve patient outcomes while also offering a cost-effective solution for healthcare providers.

On average, we spend a third of our lives in bed. Our self-positioning bed; the Korus™, combined with our AI-driven software, is designed to provide precise sleep therapies improving lifestyle and medical care that benefits sleep wellness and faster recovery at home.

Rhaeos is a pioneering company that has developed the first wearable shunt monitor to enhance care for patients with hydrocephalus. Utilizing a novel thermal biosensor, the device allows for noninvasive, real-time monitoring of cerebrospinal fluid flow. This innovative technology, born from collaborative research at Northwestern University involving experts from engineering, medicine, and management, addresses a significant clinical need by providing timely data to improve treatment for chronic medical conditions. Rhaeos's patches are designed to detect fluid flow in various bodily systems, including blood and lymph, facilitating quicker medical responses and advancing the standard of care in neurosurgery and beyond.

AegirBio AB is a Swedish diagnostics company focused on developing innovative home testing solutions for oral health, therapeutic drug monitoring, and infectious diseases. The company has established a platform that enhances lateral flow tests, significantly improving their sensitivity and precision compared to traditional methods. AegirBio's product lineup includes the Veritope technology, which measures intact natalizumab for multiple sclerosis, alongside the MagniaReader, designed for both research and veterinary use. Their advancements enable robust, affordable, and easy-to-use testing instruments applicable across human health, veterinary, food safety, and environmental sectors. By leveraging novel techniques, AegirBio aims to expand the market for lateral flow tests and enhance patient care through more reliable diagnostics.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Daxor Corporation is a medical device and biotechnology firm based in New York, specializing in blood volume measurement. The company developed the BVA-100 Blood Volume Analyzer, which is the first FDA-approved instrument designed to provide rapid and accurate measurement of a patient's true blood volume. This innovative device is utilized in diagnosing and treating various medical conditions, including congestive heart failure, hypertension, and anemia, among others. Daxor also offers additional services such as semen banking, blood storage, and laboratory testing. The company has established a cooperative research agreement with the Uniformed Services University of the Health Sciences to study the efficacy of the BVA-100 in assessing blood volume in traumatic injury contexts. Founded in 1970 and originally known as Idant Corporation, Daxor Corporation has positioned itself at the forefront of medical instrumentation technology.

NeuroGeneces utilizes advanced neuroscience, sleep expertise, and artificial intelligence to deliver brain health assessments aimed at enhancing cognitive longevity. The company has received funding from various reputable sources, including government agencies and private investors. Its flagship product is a sleep headband equipped with machine learning algorithms that analyze EEG data, comparing it against a proprietary normative database to determine an individual's biological brain age. This innovative approach allows healthcare practitioners to objectively evaluate brain function and develop targeted intervention strategies. Additionally, the device monitors sleep patterns, including quantity, quality, and heart rate variability, providing essential support for clinicians focused on wellness and preventative care. By identifying neurodegeneration early, NeuroGeneces aims to empower users to optimize their mental and physical performance.

Civatech Oncology is a medical device company based in Durham, North Carolina, that specializes in developing polymer-based devices for the treatment of cancer through localized low-dose-rate radiation. Founded in 2006, the company focuses on creating devices tailored for specific tumor types, utilizing its patented technology to manufacture them in various shapes and formats. Its flagship product, the CivaString, has received FDA 510k clearance for the treatment of any solid tumor. Civatech's innovative approach aims to enhance the efficacy of brachytherapy for early-stage cancers by reducing procedure times, ensuring uniform dose distribution, and minimizing patient trauma.

EndoTheia is a medical equipment manufacturing company specializing in the development of advanced flexible endoscopic devices. The firm's technology incorporates micro-machined smart materials to produce highly dexterous manipulators that operate at millimeter and sub-millimeter scales. This innovation aims to enhance therapeutic outcomes for healthcare professionals conducting complex flexible endoscopic procedures. Through its focus on next-generation medical technology, EndoTheia seeks to improve the efficacy and precision of endoscopic interventions in various clinical settings.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

The University of Texas MD Anderson Cancer Center is a leading institution dedicated exclusively to cancer patient care, research, education, and prevention. Located in the Texas Medical Center in Houston, Texas, it was established as one of the original three comprehensive cancer centers under the National Cancer Act of 1971. MD Anderson serves as both a degree-granting academic institution and a specialized cancer treatment facility. It is affiliated with two prominent medical schools: The University of Texas Medical School at Houston and Baylor College of Medicine. Renowned for its exceptional cancer care, MD Anderson has consistently ranked among the top cancer hospitals in the United States, earning the No. 1 position in U.S. News & World Report's "Best Hospitals" survey for ten of the past twelve years. The center is widely recognized for its commitment to advancing cancer treatment and improving patient outcomes.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

Second Sight Medical Products, founded in 1998 and located in Sylmar, California, specializes in the development and marketing of implantable visual prosthetics aimed at restoring vision for individuals who are blind due to various conditions, including Retinitis Pigmentosa, glaucoma, diabetic retinopathy, optic nerve injury, and trauma. The company's mission is to enhance the independence of blind individuals by providing innovative solutions that offer artificial vision. Through its advancements in retinal prosthesis technology, Second Sight is committed to improving the quality of life for those affected by significant visual impairments.

Prapela is a company that offers noninvasive stimulation therapy designed to enhance the health of newborns, specifically targeting issues such as irregular breathing and low oxygenation. By placing a reusable pad inside a hospital bassinet or incubator, Prapela provides gentle stimulation that supports the natural processes of breathing control and oxygenation. This therapy aims to improve cardiorespiratory outcomes while reducing the need for pharmacotherapy and minimizing the duration of conventional treatments for severe medical conditions. Since its inception, Prapela has garnered significant recognition as a leading pediatric medical device startup, receiving multiple awards and over $8 million in grants. The company collaborates with neonatologists, the National Institutes of Health, and the FDA to develop and refine its solutions, contributing to better health outcomes for newborns.

PharmaJet is a user-friendly, inexpensive device for fluid injection into the body without a needle. Able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use, and pass-along disease risk, the technology creates a positive ROI back for every injection. Unique in the field of jet injection because of its ability to reach all target tissues (IM, SC--0.5 mL, and ID--0.1 mL) accurately and comfortably, supported by wide regulatory claims (global and country-specific) PharmaJet's platforms are the only commercially available devices that effectively address the 3 B annual immunization market. It was founded in 2005 and headquartered in Golden, Colorado.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Rescue Biomedical Services is a medical equipment repair company serving Southern California.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Matregenix is a MedTech company offering advanced nanofibrous materials for medical applications. MatriNova, the first application of the platform technology is a barrier membrane with characteristics for use in periodontal surgeries. Matregenix, Inc. was founded in 2018 by Sherif Soliman and is based in Irvine, California.

Virtuoso Surgical focuses on developing robotic tools specifically for minimally invasive endoscopic surgery. The company's surgical system features needle-sized robotic arms that allow surgeons to navigate and operate in hard-to-reach areas of the body, addressing limitations posed by traditional endoscopes. By providing dexterous and accurate instruments, Virtuoso Surgical aims to enhance surgical precision and improve patient outcomes while also offering a cost-effective solution for healthcare providers.

Second Sight Medical Products, founded in 1998 and located in Sylmar, California, specializes in the development and marketing of implantable visual prosthetics aimed at restoring vision for individuals who are blind due to various conditions, including Retinitis Pigmentosa, glaucoma, diabetic retinopathy, optic nerve injury, and trauma. The company's mission is to enhance the independence of blind individuals by providing innovative solutions that offer artificial vision. Through its advancements in retinal prosthesis technology, Second Sight is committed to improving the quality of life for those affected by significant visual impairments.

Eliaz Therapeutics has developed a patented medical device that selectively removes galectin-3 from human blood, addressing currently untreatable life-threatening diseases. This device targets galectin-3, a protein associated with conditions such as diabetes, chronic kidney disease, organ fibrosis, and cancer. By employing a single-use apheresis column that utilizes a proprietary capturing molecule, the device effectively eliminates both bound and free galectin-3 from circulation. This innovative approach offers a less invasive treatment option with fewer side effects compared to traditional therapies, enabling physicians to provide effective care for patients suffering from acute kidney injury, sepsis, and other inflammatory and fibrotic diseases. The device is designed for easy integration into existing hospital practices, enhancing its potential for widespread adoption.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Enspectra Health, based in Mountain View, California, specializes in developing advanced imaging systems for medical applications. The company has created the first hand-held multiphoton imager for human use, enabling real-time imaging of live cellular anatomy beneath the skin. Its innovative device combines reflectance confocal and multiphoton laser scanning microscopy to produce multispectral images that reveal details not visible to the naked eye. This technology aids researchers and dermatologists in examining the structure and function of various tissues, including muscle, tendon, cartilage, and skin, thereby enhancing the diagnosis and treatment of skin conditions, particularly skin cancers. Enspectra Health aims to simplify the evaluation process for physicians and improve patient outcomes through its cutting-edge imaging solutions.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Bleep provides best new CPAP solution on the market. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That’s why they invented the DreamPort Sleep Solution – the world’s first-ever mask less CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn’t restrict your movement – enabling patients to get a better night’s sleep. Their goal is simple – to make the best bleeping CPAP products on the planet. They won’t stop until every sleep apnea patient is sleeping like a baby.

Delpor, Inc. is engaged in the development of innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules via a small non-mechanical subcutaneous implant. The company offers several technologies, including Prozor, which delivers antipsychotics and other small molecule drugs, and NANOPOR, designed for sustained release through specialized membrane architecture. Additionally, Delpor has developed the Delos PUMP, a self-contained device that allows for the pulsed delivery of medications at programmed intervals, benefiting treatments such as hormones for fertility, diabetes management, and pain relief. Founded in 2009 and located in San Francisco, California, Delpor aims to enhance medication adherence and patient convenience by providing an alternative to frequent injections through its implantable solutions.

ThermoGenesis Holdings, Inc. is a healthcare company that develops and commercializes automated technologies for cell-based therapies and bioprocessing. The company provides a range of solutions tailored for clinical biobanking, point-of-care applications, and immuno-oncology automation. Notable products include the CAR-TXpress platform, which enhances the manufacturing process for CAR-T immunotherapy, and the AXP Automated Cell Separation System, designed for isolating stem and progenitor cells from umbilical cord blood. Additionally, ThermoGenesis offers the BioArchive Automated Cryopreservation System for the robotic storage of cord blood samples and other cell therapeutic products. The PXP Point-of-Care System enables the automated processing of autologous stem cells at surgical centers or clinics. Other products in development include X-Series systems for cell isolation, washing, purification, and large-scale cell processing using proprietary buoyance-activated cell sorting technology. Founded in 1986 and headquartered in Rancho Cordova, California, the company was previously known as Cesca Therapeutics Inc. before rebranding in November 2019.

On average, we spend a third of our lives in bed. Our self-positioning bed; the Korus™, combined with our AI-driven software, is designed to provide precise sleep therapies improving lifestyle and medical care that benefits sleep wellness and faster recovery at home.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company focuses on creating pumpless platforms that utilize serum-free cellular mediums to facilitate communication between multi-organ systems. Their innovative technology incorporates integrated computational pharmacokinetics and pharmacodynamics modeling, allowing for live physiological response assessments through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as the liver and pancreas. This approach enables clients to predict in vivo functions without relying on animal models, advancing the field of biomedical research.

NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

Enspectra Health, based in Mountain View, California, specializes in developing advanced imaging systems for medical applications. The company has created the first hand-held multiphoton imager for human use, enabling real-time imaging of live cellular anatomy beneath the skin. Its innovative device combines reflectance confocal and multiphoton laser scanning microscopy to produce multispectral images that reveal details not visible to the naked eye. This technology aids researchers and dermatologists in examining the structure and function of various tissues, including muscle, tendon, cartilage, and skin, thereby enhancing the diagnosis and treatment of skin conditions, particularly skin cancers. Enspectra Health aims to simplify the evaluation process for physicians and improve patient outcomes through its cutting-edge imaging solutions.

Prapela is a company that offers noninvasive stimulation therapy designed to enhance the health of newborns, specifically targeting issues such as irregular breathing and low oxygenation. By placing a reusable pad inside a hospital bassinet or incubator, Prapela provides gentle stimulation that supports the natural processes of breathing control and oxygenation. This therapy aims to improve cardiorespiratory outcomes while reducing the need for pharmacotherapy and minimizing the duration of conventional treatments for severe medical conditions. Since its inception, Prapela has garnered significant recognition as a leading pediatric medical device startup, receiving multiple awards and over $8 million in grants. The company collaborates with neonatologists, the National Institutes of Health, and the FDA to develop and refine its solutions, contributing to better health outcomes for newborns.

BiVACOR, Inc., founded in 2008 and based in Houston, Texas, specializes in the design and manufacture of centrifugal heart pumps aimed at replacing the functions of failing hearts. The company has developed an innovative artificial heart-pumping device that features a compact design with a magnetically levitated rotor situated between opposing pump casings. This advanced rotary blood pump technology is engineered to deliver the necessary cardiac output while minimizing the risks of blood-cell damage and clotting. BiVACOR's team comprises skilled engineers, medical specialists, and business executives who collaborate to enhance this groundbreaking technology. The company also maintains an international office in Brisbane, Australia, fostering a strong network to support its mission.

Xtrava Health specializes in creating and commercializing user-friendly diagnostic products for both health professionals and consumers. The company focuses on developing medical devices that enhance respiratory health monitoring, employee wellness, and baby monitoring, thereby addressing practical health-related challenges. By leveraging advanced technology and forming strategic global partnerships, Xtrava aims to provide accurate and affordable diagnostic solutions that simplify the process of health monitoring for everyday users.

MRIMath specializes in medical imaging technology aimed at improving cancer diagnosis and treatment. The company develops solutions that assist oncologists and surgeons in identifying tumors and assessing treatment responses, thereby enhancing patient outcomes in oncology. MRIMath's innovative approach incorporates an interactive human-AI interface that offers a reliable and cost-effective tool for medical practitioners to monitor brain tumor growth. Beyond its imaging technology, MRIMath also provides hospital care, medical device services, and AI consulting, along with AI-powered software designed to streamline healthcare processes.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Abterra Biosciences specializes in antibody discovery and sequencing services aimed at enhancing therapeutic antibody development. The company utilizes advanced technologies, including next-generation sequencing, mass spectrometry, and machine learning, to analyze antibody responses and rapidly identify high-affinity therapeutic antibodies. Its innovative platform, Alicanto, streamlines the discovery process by identifying target-specific antibodies directly from serum, eliminating the need for traditional and time-consuming methods such as cell selection and cloning. By combining the expertise of data scientists and biologists, Abterra Biosciences aims to provide healthcare researchers with new insights and efficient solutions in the field of antibody therapeutics.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Biomotum specializes in the design and manufacturing of wearable robotic exoskeletons aimed at improving mobility for individuals facing challenges in walking. The company addresses the growing health issues related to mobility impairments, particularly for those affected by neurological disorders such as stroke and cerebral palsy. Biomotum's innovative systems integrate advanced assistive technology, offering a user-friendly therapeutic solution that features real-time training insights, compatibility with tele-rehabilitation, and built-in progress reporting. This approach enhances the rehabilitation process for users, empowering them to regain mobility and improve their quality of life.

Eysz is developing a digital health platform that measures disease progression, intervention efficacy and side effects to assist clinicians in developing a personalized care plan for neurological diseases. Doctors currently rely on patient self-reported data and subjective clinical exams to manage and treat chronic neurological disorders. The lack of a reliable biomarker in neurological disease leads to economic burdens of $1.7T in the US and Europe alone and stagnant patient outcomes with no significant improvement in outcomes in the last 30 years. Eysz is using analysis of eye-movements as a biomarker to assess brain health across neurological disorders starting with epilepsy – a disorder characterized by recurrent seizures. After completing a successful clinical study sponsored by the NIH and NSF Eysz will be releasing their first product to diagnose and monitor childhood absence epilepsy in Q3 2023.

PhotoniCare, Inc. is a medical device company based in Champaign, Illinois, founded in 2013. The company specializes in developing innovative diagnostic tools for middle ear infections, notably the TOMi Scope. This handheld device employs advanced light-based technology, specifically near-infrared light waves, to create 3D images of the middle ear by seeing through the eardrum. This capability allows physicians to visualize the middle ear directly and safely, enabling them to assess its condition quickly and accurately. By determining the contents of the middle ear, clinicians can make informed decisions regarding the need for antibiotics or surgical interventions. PhotoniCare's technology not only addresses otology but also presents potential for growth in other medical fields.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Solenic Medical, a medical device company that develops a non-invasive treatment for infected metallic implants in the body. The company leverages the properties of alternating magnetic fields (AMF) generated from external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries, such as knee and hip replacements, as well as in trauma-related implants such as plates and rods. Its AMF technology has the potential to completely replace the very expensive and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Rajiv Chopra and David Greenberg founded it in College Station, Texas in 2019.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack. The company was established in 2011 and is headquartered in Somerville, Massachusetts.

FIRMM is a software-based biofeedback solution, called Framewise Integrated Real-Time MRI Monitoring (FIRMM), for acquiring better brain MR exams.

Neuronoff, a medical device company, is focused on the development of the Injectrode™, a novel injectable metal electrode, which is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets.

Second Sight Medical Products, founded in 1998 and located in Sylmar, California, specializes in the development and marketing of implantable visual prosthetics aimed at restoring vision for individuals who are blind due to various conditions, including Retinitis Pigmentosa, glaucoma, diabetic retinopathy, optic nerve injury, and trauma. The company's mission is to enhance the independence of blind individuals by providing innovative solutions that offer artificial vision. Through its advancements in retinal prosthesis technology, Second Sight is committed to improving the quality of life for those affected by significant visual impairments.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company focuses on creating pumpless platforms that utilize serum-free cellular mediums to facilitate communication between multi-organ systems. Their innovative technology incorporates integrated computational pharmacokinetics and pharmacodynamics modeling, allowing for live physiological response assessments through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as the liver and pancreas. This approach enables clients to predict in vivo functions without relying on animal models, advancing the field of biomedical research.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.

NextStep Robotics Inc. is focused on developing innovative solutions for treating foot drop through a robotic device that enhances walking function. Incorporated in 2017 and based in Baltimore, Maryland, the company enables clinics to offer personalized robotic therapy using adaptive software that provides assistance tailored to each patient's needs. This system allows lower-skilled clinic staff to operate the device, thereby freeing up therapists to concentrate on other treatment modalities. As the company collects more data, the software will evolve into an AI-based system that optimizes training protocols for individual patients. The device is classified as a Class 1 Exercise Device, which allows for immediate revenue generation through direct sales, leasing, software subscriptions, and service contracts. This clinically proven approach not only improves patient outcomes but also enables clinics to provide reimbursable therapy for conditions that previously lacked effective treatment options.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.

Intake Health is a developer of a continuous passive health monitoring device that operates at home without requiring changes in user behavior. The device is designed to be mounted on a toilet, where it automatically tests urine from flush water to deliver lab-quality results for various health and dietary indicators. By leveraging advanced biosensors and wireless technology, the system accurately tracks hydration and nutrition by quantifying specific urinary biomarkers. Users receive instant insights on their health metrics through a mobile application, facilitating informed decision-making regarding their well-being. Intake Health aims to enhance health predictions and personalized prevention strategies through the accumulation of personalized biomarkers over time. The company has received funding from the National Science Foundation and the National Institutes of Health.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.

West Virginia University School of Medicine is dedicated to education, research, clinical care, and community service. It equips students with comprehensive medical training and promotes advancements in healthcare through innovative research. The institution features advanced medical technologies such as magnetic resonance imaging, lithotripsy, and laser surgery, which enhance both teaching and patient care. By integrating these technologies into its curriculum and services, the school aims to improve health outcomes and contribute to the overall well-being of individuals and communities.

Ramona develops advanced microscopy tools designed to enhance cellular-level research by capturing detailed images over vast areas. The company's innovative microscope employs custom control electronics to efficiently process large volumes of image data from multiple micro-cameras, allowing researchers to capture and analyze extensive gigapixel datasets. This capability not only provides a wider field of view but also enables synchronous data capture, allowing for real-time observation of cellular processes. By offering a new perspective on cellular dynamics, Ramona's technology empowers researchers to make more informed decisions quickly and effectively.

Bruin Biometrics LLC specializes in the development and manufacture of biometric-sensor based medical devices aimed at the early identification and monitoring of chronic and preventable conditions. The company offers innovative point-of-care solutions such as the Provizio SEM Scanner, a handheld wireless device designed for assessing the risk of pressure injuries and ulcers, as well as the OrthoSonos, which monitors joint health through acoustic emissions. Founded in 2009 and headquartered in Los Angeles, California, with an additional office in Manchester, United Kingdom, Bruin Biometrics is focused on delivering effective solutions for wound care and orthopedic care, emphasizing real-time data capture, analytics, and reporting. The company has licensed wireless health technologies from the UCLA Wireless Health Institute, aiming to address significant medical needs through its portfolio of patent-protected, FDA-approved devices.

VisionQuest Biomedical is a medical device company focused on leveraging artificial intelligence to prevent avoidable blindness. The company's flagship software application, EyeStar, aids in the diagnosis of diabetic retinopathy, while another application, Aspire, is designed to detect malarial retinopathy. Expanding its technological scope, VisionQuest has introduced i-RxTherm, which aims to identify early-stage diabetic diseases beyond ocular conditions. VisionQuest develops innovative image-based technologies to improve healthcare accessibility, particularly in diabetes and eye care, benefiting millions in the United States and globally. Their solutions enhance digital binocular indirect ophthalmoscopy examinations and utilize a neural network for effective analysis of retinal images captured with smartphone-based cameras, facilitating early detection of diabetic peripheral neuropathy and retinopathy of prematurity in various healthcare settings.

SOFIE focuses on advancing the field of theranostics by simplifying the adoption and application of molecular imaging and radiopharmaceuticals. The company offers a comprehensive range of imaging and radiochemistry systems, along with a robust network of radiopharmacies and contract manufacturing services to provide novel diagnostic and therapeutic agents. By developing molecular imaging probes and devices, SOFIE enables physicians to identify tumors that are responsive to targeted therapies, thereby facilitating personalized healthcare and informed treatment decisions. The company's commitment to reducing the cost and complexity of these technologies aims to enhance patient health outcomes.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

Second Sight Medical Products, founded in 1998 and located in Sylmar, California, specializes in the development and marketing of implantable visual prosthetics aimed at restoring vision for individuals who are blind due to various conditions, including Retinitis Pigmentosa, glaucoma, diabetic retinopathy, optic nerve injury, and trauma. The company's mission is to enhance the independence of blind individuals by providing innovative solutions that offer artificial vision. Through its advancements in retinal prosthesis technology, Second Sight is committed to improving the quality of life for those affected by significant visual impairments.

UCSF scientist over twenty-five (25) years, twenty-three as Director of the Laboratory for Cell Analysis (LCA). Currently Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine. • Built the LCA into one of the largest academic cytometry core facilities worldwide. • Direct contribution to grants totals well over $40M in extramural funding. • Helped design and build five commercial flow cytometers, two cell sorters, and two commercial confocal microscopes. Current work supports several developing technology fields including automated digital pathology and laser-based microdissection systems, next generation clinical cell sorters, spectral flow cytometry, chip-based cytometry and point-of-care devices, wide-field high-resolution deep tissue confocal microscopy, mass spec flow cytometry (CyTOF), and spectral in vivo imaging. Application development includes single cell genomics, new functional reporter probes for cell cycle, cellular biosensors, FRET/FRAP/FLIM reporters for monitoring protein and drug interactions, new encoded carrier technology for immune profiling and liquid arrays, and rapid identification systems for virology and microbiology. Hyun also participates in biomedical software and database design, and testing of new algorithms for cytometric data processing and presentation of results.

Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.

Autonomous Healthcare is a medical technology company focused on transforming clinical care workflows through automation. By developing advanced healthcare technologies, it aims to revolutionize critical care and peri-operative care. The company's solutions continuously analyze bedside monitoring data to identify and address adverse events, thereby enhancing patient safety and care efficiency. This innovative approach enables healthcare professionals to reduce hospital lengths of stay for patients, ultimately improving overall healthcare outcomes.

NeuraMedica is a medical device company focused on developing an innovative bioabsorbable surgical clip aimed at closing the dura mater. This advanced product enables neurosurgeons and orthopedic spine surgeons to achieve a secure dural closure much faster than traditional methods. By streamlining the procedure, NeuraMedica's solution not only reduces the duration of anesthesia but also contributes to significant cost savings for healthcare providers. The company’s technology promotes better patient outcomes, making it a valuable addition to surgical practices in neurosurgery and orthopedic spine surgery.

Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

CoapTech, Inc. is a medical device company based in Baltimore, Maryland, specializing in ultrasound-based solutions for the placement of feeding tubes. Founded in 2016, CoapTech has developed the Point-of-care Ultrasound Magnet Aligned (PUMA-G) System, which mitigates risks associated with traditional methods such as PEG blind sticks, endoscope reprocessing, and fluoroscopy by allowing for ultrasound visualization from the stomach wall to the surface. The company also offers a procedure known as Percutaneous Ultrasound Gastrostomy (PUG), designed for critical care physicians and non-surgical providers to simplify the insertion of gastrostomy tubes. Utilizing a proprietary technology called Coaptive Ultrasound, CoapTech combines magnetic device guidance with real-time ultrasound feedback, aiming to improve safety, reduce healthcare costs, and enhance patient care experiences. Their focus on the PUG procedure highlights a commitment to innovation, safety, and accessibility in medical care delivery across various patient populations.